Rafael Dal-Ré and colleagues discuss how incidental findings are likely to be viewed as potential benefits of research participation in genomics trials, and investigators should implement mechanisms to ensure provision of timely and appropriate care. Ensuring provision of such interventions in countries lacking a universal public health care system may prove challenging. Please see later in the article for the Editors' Summary
Rafael Dal-Ré, Nicholas Katsanis, Sara Katsanis, Lisa S Parker, and Carmen Ayuso.
Clinical Research Program, Pasqual Maragall Foundation, Barcelona, Spain.
PLoS Med. 2014 Jan 1; 11 (1): e1001584e1001584.
AbstractRafael Dal-Ré and colleagues discuss how incidental findings are likely to be viewed as potential benefits of research participation in genomics trials, and investigators should implement mechanisms to ensure provision of timely and appropriate care. Ensuring provision of such interventions in countries lacking a universal public health care system may prove challenging. Please see later in the article for the Editors' Summary